Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

Protalix BioTherapeutics, Inc.

Protalix Biotherapeutics develops and manufactures enzyme replacement therapies for rare diseases using their ProCellEx plant cell-based expression system.

msh id	COM:PROTALIX
symbol	PLX
name	Protalix BioTherapeutics, Inc.
homepage url	https://www.protalix.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	208
crunchbase url	-
linkedin url	-
founders	-

market cap	82.11M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-0.09
growth cost of revenue	0.17
growth depreciation and amortization	-0.47
growth ebitda	2.08
growth ebitda ratio	1.79
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-0.87
growth gross profit	0.52
growth gross profit ratio	0.1

COM:PROTALIX

Protalix Biotherapeutics

Last Close

1.69

21/11 21:00

Market Cap

82.11M

Beta: -

Volume Today

529.32K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	55.03M
cost of revenue	55.03M
depreciation and amortization	1.19M
ebitda	11.65M
ebitda ratio	0.18
eps	0.12
eps diluted	0.09
operating expenses	32.05M
operating income	10.46M
operating income ratio	0.16

accounts receivables	-428K
capital expenditure	-1.15M
cash at beginning of period	17.11M
cash at end of period	23.63M
inventory	19.05M
working capital ttm	29.26M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-